Skip to main content

Table 2 Post-Discharge Outcomes by Mineralocorticoid Receptor Antagonist (MRA) Prescription Status (N = 1463)

From: Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study

 

MRA Prescribed at Discharge (N = 365)

MRA Not Prescribed at Discharge (N = 1098)

Unadjusted Odds Ratio for MRA Prescription (ref = no MRA) (95% CI)

Adjusted Odds Ratio for MRA Prescription (ref = no MRA) (95% CI)

Interaction between MRA and Principal/ Secondary Diagnosis, p-value

30-day Readmission

81 (22.2%)

237 (21.6%)

1.04 (0.78–1.38)

1.14 (0.84–1.57)

0.53

180-day Readmission

159 (43.6%)

509 (46.4%)

0.89 (0.70–1.13)

0.86 (0.67–1.11)

0.14

30-day Mortality

11 (3.0%)

27 (2.5%)

1.23 (0.61–2.51)

1.42 (0.67–3.03)

0.34

180-day Mortality

34 (9.3%)

112 (10.2%)

0.90 (0.60–1.35)

1.17 (0.76–1.79)

0.35

30-day Heart Failure Readmission

27 (7.4%)

49 (4.5%)

1.71 (1.05–2.78)

1.60 (0.95–2.68)

0.13

180-day Heart Failure Readmission

76 (20.8%)

170 (15.5%)

1.44 (1.06–1.94)

1.02 (0.72–1.44)

0.45

30-day Hyperkalemia Readmission

7 (1.9%)

13 (1.2%)

1.63 (0.65–4.12)

1.92 (0.70–5.24)

0.62

180-day Hyperkalemia Readmission

19 (5.2%)

52 (4.7%)

1.10 (0.64–1.89)

1.00 (0.55–1.84)

0.81